Ozmosi | Repagermanium Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Repagermanium

Alternative Names: repagermanium
Clinical Status: Inactive
Latest Update: 2025-12-05
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Immunostimulant

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Dimerix Bioscience
Company Location:
Company Founding Year: 2014
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Pneumonia|COVID-19

Phase 2: COVID-19

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05122182

 CLARITY 2

P2

Terminated

COVID-19

2022-08-15

2025-08-27

2015-002340-14

 REMAP-CAP

P4

Unknown status

COVID-19|Pneumonia

2021-01-16

2025-07-07

Treatments

Recent News Events

Date

Type

Title

04/01/2023

PubMed

 GM-CSF-producing CCR2+ CCR6+ Th17 cells are pathogenic in dextran sodium sulfate-induced colitis model in mice.

02/20/2023

PubMed

 Simultaneous mitigation of arsenic and cadmium accumulation in rice grains by foliar inhibitor with ZIF-8@Ge-132.

02/01/2023

PubMed

 A hydrolysate of poly-trans-[(2-carboxyethyl)germasesquioxane] (Ge-132) suppresses Cav3.2-dependent pain by sequestering exogenous and endogenous sulfide.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions